Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy
- 1 November 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 34 (11), 3088-3090
- https://doi.org/10.1038/s41375-020-0860-7
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in JapanInternational Journal of Hematology, 2019
- Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7Leukemia, 2019
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple MyelomaThe New England Journal of Medicine, 2018
- ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALINGMediterranean Journal of Hematology and Infectious Diseases, 2017
- Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of ElotuzumabThe AAPS Journal, 2016
- Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaThe New England Journal of Medicine, 2015
- Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma CellsMolecular and Cellular Biology, 2015
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myelomaBlood, 2012
- Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cellsNature Immunology, 2009
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple MyelomaClinical Cancer Research, 2008